PDF(Pubmed)
Abstract：
UNASSIGNED: Palmoplantar warts (PWs) are a usual skin disease associated with human papillomavirus (HPV) that can affect patients\' quality of life. The traditional Chinese medicine (TCM) Weiren Xiaoyou formula (WRXYF) is a relatively gentle and effective therapy that has achieved good therapeutic effects in clinical practice, but its mechanism has not yet been studied.
UNASSIGNED: A meta-analysis was carried out to identify the potential advantages of topical TCM for PW treatment. Clinical cases suggested that WRXYF was an effective therapeutic agent against PWs. Network pharmacology was utilized to predict potential targets for the main bioactive compound, tanshinone IIA (Tan IIA), in WRXYF. High-performance liquid chromatography with electrospray mass spectrometry (HPLC/ESI-MS) was applied to detect major components. The bioactivity of Tan IIA against PWs was then validated with quantitative polymerase chain reaction (q-PCR), fluorescence in situ hybridization (FISH), electron microscopy and Western blotting.
UNASSIGNED: A meta-analysis was conducted on 10 randomized clinical trials (RCTs) involving 2260 participants suggested that topical TCM could more effectively treat PWs than conventional medications. Network pharmacology identified Tan IIA as a candidate agent from 17 major compounds assessed by HPLC/ESI-MS because of its stable binding with 10 PW targets. HPV2, HPV27, and HPV57 were the main infectious strains in tissues obtained from PW patients and in HPV-infected HaCaT cells. Tan IIA treatment effectively destroyed viral particles and reduced the viral copy numbers of the three HPV subtypes. The results shown that Tan IIA has the ability to halt the cell cycle of HPV-infected HaCaT cells specifically in the G0/G1 phase. A total of 6 cell cycle-related proteins were regulated after Tan IIA treatment, demonstrating the role of Tan IIA in inhibiting the cell cycle.
UNASSIGNED: Tan IIA, the primary bioactive constituent in WRXYF, enhances PWs by halting the cell cycle in the G0/G1 phase via modulation of the p53 signaling pathway.
UNASSIGNED: A meta-analysis was carried out to identify the potential advantages of topical TCM for PW treatment. Clinical cases suggested that WRXYF was an effective therapeutic agent against PWs. Network pharmacology was utilized to predict potential targets for the main bioactive compound, tanshinone IIA (Tan IIA), in WRXYF. High-performance liquid chromatography with electrospray mass spectrometry (HPLC/ESI-MS) was applied to detect major components. The bioactivity of Tan IIA against PWs was then validated with quantitative polymerase chain reaction (q-PCR), fluorescence in situ hybridization (FISH), electron microscopy and Western blotting.
UNASSIGNED: A meta-analysis was conducted on 10 randomized clinical trials (RCTs) involving 2260 participants suggested that topical TCM could more effectively treat PWs than conventional medications. Network pharmacology identified Tan IIA as a candidate agent from 17 major compounds assessed by HPLC/ESI-MS because of its stable binding with 10 PW targets. HPV2, HPV27, and HPV57 were the main infectious strains in tissues obtained from PW patients and in HPV-infected HaCaT cells. Tan IIA treatment effectively destroyed viral particles and reduced the viral copy numbers of the three HPV subtypes. The results shown that Tan IIA has the ability to halt the cell cycle of HPV-infected HaCaT cells specifically in the G0/G1 phase. A total of 6 cell cycle-related proteins were regulated after Tan IIA treatment, demonstrating the role of Tan IIA in inhibiting the cell cycle.
UNASSIGNED: Tan IIA, the primary bioactive constituent in WRXYF, enhances PWs by halting the cell cycle in the G0/G1 phase via modulation of the p53 signaling pathway.
摘要：
■掌plant疣（PWs）是与人乳头瘤病毒（HPV）相关的常见皮肤病，可影响患者的生活质量。中药微人消瘤方(WRXYF)是一种相对温和有效的治疗方法,在临床上取得了良好的治疗效果,但其机制尚未研究。
■进行了荟萃分析，以确定局部中药治疗PW的潜在优势。临床病例表明，WRXYF是一种有效的治疗PWs的药物。网络药理学用于预测主要生物活性化合物的潜在靶标，丹参酮IIA(TanIIA),在WRXYF。采用高效液相色谱-电喷雾质谱(HPLC/ESI-MS)检测主要成分。然后用定量聚合酶链反应（q-PCR）验证TanIIA对PWs的生物活性，荧光原位杂交（FISH），电子显微镜和蛋白质印迹。
■对10项随机临床试验（RCT）进行了荟萃分析，涉及2260名参与者，表明外用中药可以比常规药物更有效地治疗PWs。网络药理学将TanIIA鉴定为通过HPLC/ESI-MS评估的17种主要化合物的候选试剂,因为其与10个PW靶标稳定结合。HPV2，HPV27和HPV57是PW患者组织和HPV感染的HaCaT细胞中的主要感染菌株。TanIIA处理有效地破坏了病毒颗粒并减少了三种HPV亚型的病毒拷贝数。结果显示TanIIA具有特异性地在G0/G1期停止HPV感染的HaCaT细胞的细胞周期的能力。共有6种细胞周期相关蛋白在TanIIA处理后受到调控,证明了TanIIA在抑制细胞周期中的作用。
■TanIIA，WRXYF中的主要生物活性成分，通过调节p53信号通路使G0/G1期细胞周期停止来增强PWs。
■进行了荟萃分析，以确定局部中药治疗PW的潜在优势。临床病例表明，WRXYF是一种有效的治疗PWs的药物。网络药理学用于预测主要生物活性化合物的潜在靶标，丹参酮IIA(TanIIA),在WRXYF。采用高效液相色谱-电喷雾质谱(HPLC/ESI-MS)检测主要成分。然后用定量聚合酶链反应（q-PCR）验证TanIIA对PWs的生物活性，荧光原位杂交（FISH），电子显微镜和蛋白质印迹。
■对10项随机临床试验（RCT）进行了荟萃分析，涉及2260名参与者，表明外用中药可以比常规药物更有效地治疗PWs。网络药理学将TanIIA鉴定为通过HPLC/ESI-MS评估的17种主要化合物的候选试剂,因为其与10个PW靶标稳定结合。HPV2，HPV27和HPV57是PW患者组织和HPV感染的HaCaT细胞中的主要感染菌株。TanIIA处理有效地破坏了病毒颗粒并减少了三种HPV亚型的病毒拷贝数。结果显示TanIIA具有特异性地在G0/G1期停止HPV感染的HaCaT细胞的细胞周期的能力。共有6种细胞周期相关蛋白在TanIIA处理后受到调控,证明了TanIIA在抑制细胞周期中的作用。
■TanIIA，WRXYF中的主要生物活性成分，通过调节p53信号通路使G0/G1期细胞周期停止来增强PWs。
